HK1219883A1 - 磺烷基醚環糊精組合物 - Google Patents

磺烷基醚環糊精組合物

Info

Publication number
HK1219883A1
HK1219883A1 HK16107928.4A HK16107928A HK1219883A1 HK 1219883 A1 HK1219883 A1 HK 1219883A1 HK 16107928 A HK16107928 A HK 16107928A HK 1219883 A1 HK1219883 A1 HK 1219883A1
Authority
HK
Hong Kong
Prior art keywords
sulfoalkyl ether
ether cyclodextrin
cyclodextrin compositions
compositions
sulfoalkyl
Prior art date
Application number
HK16107928.4A
Other languages
English (en)
Inventor
．安特爾
Original Assignee
Cydex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41215591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1219883(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cydex Pharmaceuticals Inc filed Critical Cydex Pharmaceuticals Inc
Publication of HK1219883A1 publication Critical patent/HK1219883A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK16107928.4A 2008-04-28 2016-07-07 磺烷基醚環糊精組合物 HK1219883A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4851808P 2008-04-28 2008-04-28
US12/404,174 US7635773B2 (en) 2008-04-28 2009-03-13 Sulfoalkyl ether cyclodextrin compositions

Publications (1)

Publication Number Publication Date
HK1219883A1 true HK1219883A1 (zh) 2017-04-21

Family

ID=41215591

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16107928.4A HK1219883A1 (zh) 2008-04-28 2016-07-07 磺烷基醚環糊精組合物

Country Status (14)

Country Link
US (7) US7635773B2 (zh)
EP (2) EP3363430A1 (zh)
JP (5) JP4923144B2 (zh)
KR (1) KR101314803B1 (zh)
CN (3) CN114053423A (zh)
AU (1) AU2009241858B2 (zh)
BR (1) BRPI0905080B8 (zh)
CA (2) CA2702603C (zh)
EA (1) EA031355B1 (zh)
HK (1) HK1219883A1 (zh)
IL (2) IL208956A (zh)
MX (2) MX352459B (zh)
NZ (1) NZ589290A (zh)
WO (1) WO2009134347A2 (zh)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006141358A (ru) 2004-04-23 2008-05-27 Сайдекс, Инк. (Us) Препаративная форма для ингалятора сухого порошка, содержащая простой сульфоалкиловый эфир циклодекстрина
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
EP2583668B1 (en) * 2005-10-26 2014-10-08 CyDex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
MX2009011619A (es) 2007-04-27 2010-01-18 Cydex Pharmaceuticals Inc Formulaciones que contienen clopidogrel y eter sulfoalquilico-ciclodextrina y metodos de uso.
WO2009048947A1 (en) * 2007-10-09 2009-04-16 Board Of Regents, The University Of Texas System Methods of treatment of opioid tolerance, physical dependence, pain, and addiction with inhibitors of certain growth factor receptors
US7635773B2 (en) * 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
BRPI0919668A2 (pt) 2008-10-21 2018-05-29 Onyx Therapeutics, Inc. terapia de combinação com epóxi-cetonas de peptídeo
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
WO2010132711A1 (en) 2009-05-13 2010-11-18 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
EA022890B1 (ru) 2009-05-29 2016-03-31 Сидекс Фармасьютикалз, Инк. Инъецируемые композиции мелфалана, содержащие производное циклодекстрина, и способы их применения
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
CN107049935A (zh) 2010-06-29 2017-08-18 默沙东公司 取代β‑环糊精稳定的泊沙康唑静脉输注液制剂
EP3632432B1 (en) 2010-10-21 2022-09-14 Rtu Pharmaceuticals LLC Ready to use ketorolac formulations
RU2599036C2 (ru) 2011-01-26 2016-10-10 Аллерган, Инк. Андрогенная композиция для лечения офтальмологического заболевания
CA2831213C (en) * 2011-03-27 2016-05-17 Cellresin Technologies, Llc Cyclodextrin compositions, articles, and methods
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
TW201336527A (zh) 2012-02-10 2013-09-16 Alcon Res Ltd 具增強的穩定性之水性藥學組成物
DK2814849T3 (da) 2012-02-15 2020-03-09 Cydex Pharmaceuticals Inc Fremgangsmåde til fremstilling af cyclodextrin-derivater
KR101633479B1 (ko) 2012-02-28 2016-07-08 사이덱스 파마슈티칼스, 인크. 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법
KR101905937B1 (ko) 2012-03-30 2018-10-08 자피오텍 게엠베하 안토시아니딘 복합체
CA2869057C (en) * 2012-03-30 2019-07-09 Sapiotec Gmbh Use of delphinidin against staphylococcus aureus
CA2873044C (en) 2012-05-08 2021-01-26 Onyx Therapeutics, Inc. Cylodextrin complexation methods for formulating peptide proteasome inhibitors
CN102718891A (zh) * 2012-06-04 2012-10-10 咸阳西秦生物科技有限公司 利用膜分离与溶剂沉淀纯化制备磺丁基醚-β-环糊精的方法
GB201211153D0 (en) * 2012-06-22 2012-08-08 Farmhispania Pharmaceutical compositions
US20150258202A1 (en) * 2012-10-17 2015-09-17 Sapiotec Gmbh Anthocyanidin complex for the treatment of multiple myeloma
MX360192B (es) * 2012-10-22 2018-10-24 Cydex Pharmaceuticals Inc Composiciones de ciclodextrinas alquiladas y procesos para preparar y usar las mismas.
US9925274B2 (en) 2012-11-15 2018-03-27 Sapiotec Gmbh Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient
CN102993338B (zh) * 2012-12-04 2015-06-10 陕西科技大学 磺丁基-α-环糊精及其制备方法
KR20150107742A (ko) * 2012-12-11 2015-09-23 자피오텍 게엠베하 흑색종 세포를 퇴치하기 위한 델피니딘
GB201312737D0 (en) * 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
CN103694376B (zh) * 2014-01-10 2016-04-13 凯莱英医药集团（天津）股份有限公司 一种制备磺丁基醚-β-环糊精的方法
EP2913366A1 (de) * 2014-02-28 2015-09-02 SapioTec GmbH Anthocyanidin-Komplex
EP2913050A1 (de) 2014-02-28 2015-09-02 SapioTec GmbH Verfahren zur Herstellung eines Flurankomplexes
JP2017523260A (ja) 2014-05-29 2017-08-17 ユーティーアイ リミテッド パートナーシップ シクロデキストリン系のポリアニオン性デンドリマーおよび非イオン性デンドリマー
US10851184B2 (en) 2014-08-22 2020-12-01 Cydex Pharmaceuticals, Inc. Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same
CN104874422B (zh) * 2015-04-02 2017-07-21 安徽师范大学 吡啶‑金刚烷胺配合物/β‑环糊精包合物及其制备方法和应用
WO2016195476A1 (en) 2015-05-29 2016-12-08 Erasmus University Medical Center Rotterdam Treatment of cardiac arrhythmias
WO2017007805A1 (en) 2015-07-09 2017-01-12 Gilead Sciences, Inc. Intravenous formulations of a late sodium current inhibitor
CN104974275A (zh) * 2015-07-30 2015-10-14 淄博千汇生物科技有限公司 磺烷基醚环糊精衍生物的合成方法
PT109117B (pt) * 2016-01-28 2019-02-01 Hovione Farm Sa Complexação de ingredientes ativos farmacêuticos
MX2018013584A (es) * 2016-05-09 2019-04-01 Xellia Pharmaceuticals Aps Formulaciones de antibioticos glicopeptidicos estabilizados.
US11274164B2 (en) * 2017-02-07 2022-03-15 Biophore India Pharmaceuticals Pvt. Ltd. Method for the preparation of sulfobutylether beta cyclodextrin sodium
CN111093627B (zh) 2017-07-11 2024-03-08 吉利德科学公司 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
US10322114B2 (en) 2017-07-31 2019-06-18 Above And Beyond Nb, Llc Formulation of a riluzole solution with beta-cyclodextrins
CN108034011A (zh) * 2017-12-28 2018-05-15 山东滨州智源生物科技有限公司 一种绿色高效环糊精衍生物生产精制工艺
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
CN110575826A (zh) * 2019-09-16 2019-12-17 天津科技大学 一种磺酸基环糊精衍生物及其修饰的纳米二氧化钛的制备方法
CN113151246B (zh) * 2021-02-18 2022-06-21 杭州楠大环保科技有限公司 易腐垃圾降解菌剂及其应用
US11649299B2 (en) 2021-06-10 2023-05-16 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Purification of sulfobutylated cyclodextrins with specific ion exchange resins
WO2023205165A1 (en) * 2022-04-22 2023-10-26 Brii Biosciences Offshore Limited A polymyxin composition and methods for producing the same
CN115505052B (zh) * 2022-08-23 2023-05-23 安徽普利药业有限公司 一种β-环糊精衍生物的制备方法

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2744938A (en) 1952-07-24 1956-05-08 Universal Oil Prod Co Removal of color impurities from organic compounds
US3033900A (en) 1958-03-25 1962-05-08 Pfanstiehl Lab Inc Method of preparing calcium glucoheptonate
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
CA978308A (en) 1971-09-09 1975-11-25 Scott Paper Company Use of activated carbon to recover and separate chemicals produced during pulping operations
US4292176A (en) 1976-12-08 1981-09-29 Standard Oil Company (Indiana) Use of activated carbon in waste water treating process
JPS5953038B2 (ja) 1979-04-07 1984-12-22 メルシャン株式会社 サイクロデキストリンの製造法
NL8104410A (nl) 1981-09-24 1983-04-18 Proefstation Voor Aardappelver Werkwijze ter bereiding van cyclodextrine.
JPS5862152A (ja) 1981-10-08 1983-04-13 Microbial Chem Res Found Ｎ−〔４−（３−アミノプロピル）アミノブチル〕−２−（ω−グアニジノ脂肪酸アミド）−２−ヒドロキシエタンアミドおよびその誘導体ならびにその製造法
US4818411A (en) 1983-12-16 1989-04-04 Ecolochem, Inc. Deoxygenation process
HU194939B (en) 1983-12-22 1988-03-28 Chinoin Gyogyszer Es Vegyeszet Process for producing alpha- beta- and gamma cyclodextrine of high yield capacity
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
JPS61169149A (ja) 1985-01-22 1986-07-30 Nippon Mining Co Ltd 連続鋳造方法
US4597946A (en) 1985-04-30 1986-07-01 Uop Inc. Vertical tube reactor with serial downward flow through a plurality of sets of particulate containing tubes
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US4920214A (en) 1986-04-16 1990-04-24 American Maize-Products Company Process for producing modified cyclodextrins
US4738923A (en) 1986-05-20 1988-04-19 American Maize-Products Company Process for producing and separating cyclodextrins
DE3789101T2 (de) 1986-12-19 1994-07-21 Sankyo Co Renin inhibierende Oligopeptide, ihre Präparation und ihre Anwendung.
US5760015A (en) 1988-01-19 1998-06-02 The Trustees Of The University Of Pennsylvania Cyclodextrin compounds and methods of making and use thereof
US5658894A (en) 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
US5135919A (en) 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5183809A (en) 1990-02-15 1993-02-02 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Cyclodextrin polymers and cyclodextrins immobilized on a solid surface
US5019562A (en) 1988-01-19 1991-05-28 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Growth inhibiting agent and the use thereof
US4904306A (en) 1988-07-22 1990-02-27 American Maize-Products Company Separation and purification of gamma cyclodextrin
US5007967A (en) 1988-08-15 1991-04-16 American Maize-Products Company Separation and purification of branched beta cyclodextrins
US5173481A (en) 1989-04-03 1992-12-22 The United States Of America As Represented By The Department Of Health And Human Services Preparation of specifically substituted cyclodextrins
ES2116982T3 (es) 1989-04-03 1998-08-01 Janssen Pharmaceutica Nv Sustituciones regioselectivas en ciclodextrinas.
US5257985A (en) 1989-12-04 1993-11-02 Richard Puhl Multi-chamber intravenous bag apparatus
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5241059A (en) 1990-05-21 1993-08-31 Toppan Printing Co., Ltd. Cyclodextrin derivatives
JP2905573B2 (ja) 1990-06-28 1999-06-14 日本食品化工株式会社 ヒドロキシアルキル化シクロデキストリン精製物及びその製造法
FR2668163B1 (fr) 1990-10-18 1993-01-15 Orsan Procede de fabrication de beta-cyclodextrine.
JPH051102A (ja) 1991-05-29 1993-01-08 Toppan Printing Co Ltd シクロデキストリン誘導体
CN1072185A (zh) 1991-11-13 1993-05-19 美国玉米产品公司 制备非混浊型环糊精的方法
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
EP0589578B1 (en) 1992-09-24 1998-12-23 Terumo Kabushiki Kaisha Sulfonated compounds of beta-cyclodextrin polymer and inhibitory drug for vascular wall hyperplasia containing the same
FR2705963B1 (fr) 1993-06-03 1995-07-13 Commissariat Energie Atomique Dérivés sulfonés de cyclomalto-oligosaccharides, leur procédé de préparation et support de substances actives contenant ces dérivés.
US5393880A (en) 1993-06-17 1995-02-28 American Maize-Products Company Cyclodextrin refining process
US5568756A (en) * 1993-08-31 1996-10-29 Peterson; Carl J. Support means for a saw machine
DE4333598A1 (de) 1993-10-01 1995-04-06 Consortium Elektrochem Ind Verfahren zur Herstellung von alkylierten Cyclodextrin-Derivaten, nach dem Verfahren herstellbare methylierte Cyclodextrin-Derivate und die Verwendung der Produkte
US5479254A (en) 1993-10-22 1995-12-26 Woskov; Paul P. Continuous, real time microwave plasma element sensor
US5661151A (en) 1993-12-21 1997-08-26 Schering Corporation Tetrahydrofuran antifungals
DE4401618A1 (de) 1994-01-20 1995-07-27 Consortium Elektrochem Ind Verfahren zur Herstellung von aminofunktionellen Cyclodextrin Derivaten
US5494869A (en) 1994-03-29 1996-02-27 Calgon Carbon Corporation Process for regenerating nitrogen-treated carbonaceous chars used for hydrogen sulfide removal
US5658390A (en) 1994-06-29 1997-08-19 American Maize-Products Company Purification of beta cyclodextrin
DE4428654A1 (de) 1994-08-12 1996-02-15 Consortium Elektrochem Ind Wasserlösliche Cyclodextrinderivate mit lipophilen Substituenten und Verfahren zu ihrer Herstellung
US5550222A (en) 1994-12-14 1996-08-27 American Maize-Products Company Process for producing gamma-cyclodextrin
DE4446891A1 (de) 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
DE19505263A1 (de) * 1995-02-16 1996-08-22 Consortium Elektrochem Ind Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten
US5569756A (en) 1995-03-21 1996-10-29 American Maize-Products Company Purification of chemically modified cyclodextrins
US6057262A (en) 1995-05-19 2000-05-02 University Of Kentucky Research Foundation Activated carbon and process for making same
US5614459A (en) 1995-06-07 1997-03-25 Universidad De Antioquia Process for making activated charcoal
FR2735136B1 (fr) 1995-06-08 1997-08-14 Roquette Freres Composition pulverulente d'hydroxypropyl-betacyclodextrine et son procede de preparation.
US5935941A (en) 1997-10-24 1999-08-10 Pitha; Josef Alkylations of cyclodextrins leading to derivatives which have a ridgidly extended cavity
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6033573A (en) * 1997-05-29 2000-03-07 The United States Of America As Represented By The Secretary Of Agriculture Activated nutshell carbons from agricultural waste
US6133248A (en) 1997-06-13 2000-10-17 Cydex, Inc. Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof
PT889056E (pt) * 1997-07-01 2006-07-31 Pfizer Prod Inc Processo para produzir um,a ciclodextrina.
US6316613B1 (en) * 1997-07-25 2001-11-13 Beckman Coulter, Inc. Chiral separation of pharmaceutical compounds with charged cyclodextrins using capillary electrophoresis
WO1999009997A1 (en) 1997-08-26 1999-03-04 Board Of Regents, The University Of Texas System Edta and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
ATE324122T1 (de) 1997-08-26 2006-05-15 Univ Texas Verwendung einer zusammensetzung die einen chelatbildner und eine antimikrobielle verbindung enthaltet zur behandlung von biofilmen
US6391862B1 (en) 1997-10-14 2002-05-21 The Texas A&M University System Chiral resolving agents for enantioseparations
WO1999027932A1 (en) 1997-12-01 1999-06-10 Schering Corporation Injectable antifungal formulations
AU759280C (en) 1998-02-23 2004-01-22 Cyclops, Ehf High-energy cyclodextrin complexes
TW394749B (en) * 1998-03-05 2000-06-21 Deng Jian Lang Method of manufacturing active carbon by using carbon black
AT410321B (de) 1998-08-11 2003-03-25 Tulln Zuckerforschung Gmbh Verfahren zur herstellung von cyclodextrin
DE19983660T1 (de) 1998-10-20 2001-09-13 Ben Venue Lab Inc Verfahren zur Aufreinigung von Lösungsmitteln, die bei der Herstellung von pharmazeutischen Zusammensetzungen nützlich sind
US6831099B1 (en) 1999-05-12 2004-12-14 Yale University Enzyme inhibition
DE19930553A1 (de) 1999-07-02 2001-01-11 Wacker Chemie Gmbh Verfahren zur Herstellung von alkylierten Cyclodextrin-Derivaten
AU5975700A (en) 1999-07-02 2001-01-22 Janssen Pharmaceutica N.V. Nasal formulation of an antifungal
TWI242015B (en) 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
US6479467B1 (en) 1999-12-16 2002-11-12 Eastman Chemical Company Cyclodextrin ethers
FR2808691B1 (fr) 2000-05-12 2005-06-24 Coletica Cyclodextrines substituees preferentiellement sur leur face primaire par des fonctions acide ou amine
EP1425311A4 (en) * 2001-01-11 2004-12-01 Eastman Chem Co CYCLODEXTRINSULFONATES, GUEST INCLUDING COMPLEXES, METHOD FOR THEIR PRODUCTION AND RELATED MATERIALS
AU2002254309B2 (en) 2001-03-20 2006-02-02 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
EP1498389A4 (en) 2002-04-22 2010-10-20 Kuraray Chemical Kk PROCESS FOR PRODUCING ACTIVE CHARCOAL, POLARIZABLE ELECTRODE AND CAPACITOR WITH DOUBLE ELECTRIC LAYER
US6869939B2 (en) 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US6709746B2 (en) 2002-06-05 2004-03-23 Arteva North America S.á.r.l. Reducing concentration of organic materials with substituted cyclodextrin compound in polyester packaging materials
RU2342931C2 (ru) 2002-08-20 2009-01-10 Бристол-Маерс Сквибб Компани Состав на основе комплекса арипипразола
MXPA05002728A (es) 2002-09-13 2005-07-25 Cydex Inc Capsulas que contienen composiciones de relleno acuoso estabilizadas con ciclodextrina derivada.
EP1587525A4 (en) 2003-01-14 2008-09-10 Teva Pharma PARENTERAL FORMULATIONS OF A PEPTIDE FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATODES
DK1594434T3 (da) 2003-01-14 2017-01-02 Yeda Res & Dev Company Ltd At The Weizmann Inst Of Science Parenterale formuleringer af peptide til behandling af systemisk lupus erythematosus
EP1625135B1 (fr) 2003-02-27 2009-04-08 Glaxo Group Limited Composition de fondaparinux sodique de haute purete
KR20060121908A (ko) 2003-10-10 2006-11-29 디에스엠 아이피 어셋츠 비.브이. 활성 탄소의 처리
CA2543443A1 (en) * 2003-10-31 2005-05-12 The University Of Kansas Sulfoalkyl ether-alkyl ether cyclodextrin derivatives
US20070020196A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
RU2006141358A (ru) 2004-04-23 2008-05-27 Сайдекс, Инк. (Us) Препаративная форма для ингалятора сухого порошка, содержащая простой сульфоалкиловый эфир циклодекстрина
BRPI0509592A (pt) 2004-05-06 2007-09-25 Cydex Inc formulações de sabor mascarado, contendo sertralina e ciclodextrina de éter de sulfoalquila
CA2565407A1 (en) 2004-05-10 2005-11-24 Proteolix, Inc. Compounds for enzyme inhibition
US7559241B2 (en) 2004-05-27 2009-07-14 Sulphco, Inc. High-throughput continuous-flow ultrasound reactor
US20060009469A1 (en) 2004-05-28 2006-01-12 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmacutical compositions of posaconazole
RU2006138907A (ru) 2004-06-08 2008-07-20 Метабазис Терапеутикс Синтез сложных циклических эфиров с применением кислоты льюиса
US20060045850A1 (en) * 2004-08-30 2006-03-02 Qpharma, Llc Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids
US20060079720A1 (en) 2004-10-13 2006-04-13 Milliken & Company Method for preparing acetal-containing compositions
PL2261236T3 (pl) 2004-12-07 2015-12-31 Onyx Therapeutics Inc Kompozycja do hamowania proteasomu
US20060128653A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
TW200710091A (en) 2005-04-11 2007-03-16 Tibotec Pharm Ltd (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
US7893040B2 (en) 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
CN101218174B (zh) 2005-09-29 2012-02-29 昭和电工株式会社 活性炭及其制造方法
WO2007047253A2 (en) 2005-10-11 2007-04-26 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
EP2583668B1 (en) * 2005-10-26 2014-10-08 CyDex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
CN100503647C (zh) * 2005-11-02 2009-06-24 南京师范大学 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
US20080194519A1 (en) 2006-09-15 2008-08-14 Regents Of The University Of Minnesota Topiramate compositions and methods for their use
US20090239942A1 (en) 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
MX2009011619A (es) 2007-04-27 2010-01-18 Cydex Pharmaceuticals Inc Formulaciones que contienen clopidogrel y eter sulfoalquilico-ciclodextrina y metodos de uso.
EP1992334A1 (en) 2007-05-08 2008-11-19 Docpharma NV/SA Storage-stable formulation of oxidation-sensitive phenolic drug, especially paracetamol, comprises aqueous drug solution deoxygenated by a temperature-controlled manufacturing process of the formulation
WO2008140782A2 (en) 2007-05-10 2008-11-20 Proteolix, Inc. Compounds for enzyme inhibition
EP2018866A1 (en) 2007-07-27 2009-01-28 Sandoz AG Pharmaceutical compositions containing voriconazole
WO2009018069A2 (en) 2007-07-30 2009-02-05 Cydex Pharmaceuticals, Inc Mixtures of cyclodextrin derivatives
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
TWI501773B (zh) 2007-10-04 2015-10-01 Onyx Therapeutics Inc 結晶肽環氧酮蛋白酶抑制劑以及胺基酸酮環氧化物之合成
AU2008317315A1 (en) 2007-10-26 2009-04-30 Rexahn Pharmaceuticals, Inc. Pharmaceutical formulation of clavulanic acid
JP5274878B2 (ja) 2008-04-15 2013-08-28 パナソニック株式会社 半導体装置及びその製造方法
EP2278957A2 (en) 2008-04-15 2011-02-02 Schering Corporation Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
US7635773B2 (en) * 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
WO2010132711A1 (en) 2009-05-13 2010-11-18 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
EA022890B1 (ru) 2009-05-29 2016-03-31 Сидекс Фармасьютикалз, Инк. Инъецируемые композиции мелфалана, содержащие производное циклодекстрина, и способы их применения
US8492538B1 (en) 2009-06-04 2013-07-23 Jose R. Matos Cyclodextrin derivative salts
CN107049935A (zh) 2010-06-29 2017-08-18 默沙东公司 取代β‑环糊精稳定的泊沙康唑静脉输注液制剂
CN102040675B (zh) 2010-12-22 2012-10-03 石药集团中诺药业（石家庄）有限公司 一种羟丙基-β-环糊精的制备方法
DK2814849T3 (da) * 2012-02-15 2020-03-09 Cydex Pharmaceuticals Inc Fremgangsmåde til fremstilling af cyclodextrin-derivater
KR101633479B1 (ko) 2012-02-28 2016-07-08 사이덱스 파마슈티칼스, 인크. 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법
SG194417A1 (en) 2012-05-08 2013-12-30 Onyx Therapeutics Inc Cylodextrin complexation methods for formulating peptide proteasome inhibitors
MX360192B (es) * 2012-10-22 2018-10-24 Cydex Pharmaceuticals Inc Composiciones de ciclodextrinas alquiladas y procesos para preparar y usar las mismas.
US10851184B2 (en) 2014-08-22 2020-12-01 Cydex Pharmaceuticals, Inc. Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same
CN104892797B (zh) 2015-05-28 2017-03-22 天津大学 特定平均取代度磺丁基醚‑β‑环糊精的合成方法
CN104974275A (zh) 2015-07-30 2015-10-14 淄博千汇生物科技有限公司 磺烷基醚环糊精衍生物的合成方法

Also Published As

Publication number Publication date
EP2268269A2 (en) 2011-01-05
EA201000828A1 (ru) 2011-10-31
CA2702603C (en) 2012-06-19
IL243654B (en) 2019-07-31
AU2009241858B2 (en) 2015-09-17
BRPI0905080A2 (pt) 2015-06-30
NZ589290A (en) 2012-12-21
MX2010004900A (es) 2010-06-07
IL208956A0 (en) 2011-01-31
JP2015110671A (ja) 2015-06-18
US7635773B2 (en) 2009-12-22
KR20110010742A (ko) 2011-02-07
BRPI0905080B1 (pt) 2019-04-30
US9200088B2 (en) 2015-12-01
CA2771879A1 (en) 2009-11-05
EP3363430A1 (en) 2018-08-22
US20100093663A1 (en) 2010-04-15
EP2268269A4 (en) 2011-08-17
CN114053423A (zh) 2022-02-18
CA2702603A1 (en) 2009-11-05
JP6039721B2 (ja) 2016-12-07
US8410077B2 (en) 2013-04-02
MX352459B (es) 2017-11-27
JP2018052991A (ja) 2018-04-05
WO2009134347A3 (en) 2010-01-14
EA031355B1 (ru) 2018-12-28
JP2017019879A (ja) 2017-01-26
IL208956A (en) 2016-02-29
JP6276828B2 (ja) 2018-02-07
US10780177B2 (en) 2020-09-22
JP6444548B2 (ja) 2018-12-26
AU2009241858A1 (en) 2009-11-05
US20130184357A1 (en) 2013-07-18
BRPI0905080B8 (pt) 2021-05-25
JP2012072160A (ja) 2012-04-12
US11806402B2 (en) 2023-11-07
WO2009134347A2 (en) 2009-11-05
JP4923144B2 (ja) 2012-04-25
JP2010539193A (ja) 2010-12-16
IL243654A0 (en) 2016-02-29
US20090270348A1 (en) 2009-10-29
CN101959508A (zh) 2011-01-26
US10117951B2 (en) 2018-11-06
US20190070303A1 (en) 2019-03-07
US20160158384A1 (en) 2016-06-09
KR101314803B1 (ko) 2013-10-10
CN105288650A (zh) 2016-02-03
US20210093727A1 (en) 2021-04-01
US20160346405A1 (en) 2016-12-01
US9750822B2 (en) 2017-09-05

Similar Documents

Publication Publication Date Title
HK1219883A1 (zh) 磺烷基醚環糊精組合物
SI2634231T1 (sl) Sestavki
GB0810404D0 (en) Compositions
ZA201103926B (en) Stable sulfoximine-insecticide compositions
ZA201007403B (en) Super fast acting-insulin compositions
PL2283101T3 (pl) Kompozycje na bazie wodorofluoroolefin
PL2283102T3 (pl) Kompozycje wodorofluoroolefin
EP2225351A4 (en) RENEWABLE COMPOSITIONS
GB0811302D0 (en) Shampoo compositions
EP2236559A4 (en) ether composition
HK1159668A1 (en) Multi-cure compositions
GB0812041D0 (en) Compositions
GB0808537D0 (en) Compositions
IL199812A0 (en) Cyclodextrin formulations
GB0818804D0 (en) Compositions
EP2197828A4 (en) FULLERENE MULTI-ADDUCT COMPOSITIONS
ZA201103338B (en) Cleansing compositions
PL2313178T3 (pl) Kompozycje redukujące aldehyd
EP2404987A4 (en) PERFUME COMPOSITIONS
PT2376060E (pt) Composições de nanopartículas
EP2259934A4 (en) NEW MIKTOPOLYMERIC COMPOSITIONS
GB0822112D0 (en) Compositions
GB0809354D0 (en) Compositions
GB0812197D0 (en) Compositions
GB0805099D0 (en) Claening compositions